Amgen stock returns 13.3% annually over 15 years

0 min read Updated on 08 Jul 2026, 01:05 AM

Reviewed by

Radhika SScanX News Team

AI Summary

Amgen has delivered an average annual return of 13.3% over the last 15 years, outperforming the market by 1.05% annually. With a current market capitalization of $202.05 billion, a $100 investment made 15 years ago would now be worth $647.28.

*this image is generated using AI for illustrative purposes only.

Amgen has outperformed the market over the past 15 years by 1.05% on an annualized basis, producing an average annual return of 13.3%. The company currently holds a market capitalization of $202.05 billion. This performance highlights the impact of compounded returns on long-term cash growth.

Investment Growth Analysis

An investor who purchased $100 of Amgen stock 15 years ago would see that investment grow to $647.28 today. This valuation is based on a current share price of $374.17.

Key Performance Metrics

Metric	Value
Average Annual Return	13.3%
Market Outperformance	1.05%
Current Market Cap	$202.05 billion
Current Share Price	$374.17
15-Year Growth on $100	$647.28

What factors could drive Amgen's future growth beyond its historical 13.3% annual return?

How might Amgen's market capitalization evolve in response to upcoming drug pipeline developments?

What risks could threaten Amgen's ability to maintain its market outperformance in the next decade?

Read Next Article

EMA recommends revoking marketing authorization for Amgen's Tavneos

0 min read Updated on 26 Jun 2026, 04:37 PM

Reviewed by

Ashish TScanX News Team

Add as a preferred
source on Google

AI Summary

The European Medicines Agency (EMA) has recommended the revocation of the marketing authorization for Amgen's Tavneos following an Article 20 procedure review. The recommendation is based on an assessment of the drug's benefit-risk balance. The final decision rests with the European Commission.

*this image is generated using AI for illustrative purposes only.

The European Medicines Agency (EMA) has recommended the revocation of the marketing authorization for Amgen's Tavneos. This decision follows a review conducted under the Article 20 procedure, which assesses the benefit-risk balance of authorized medicines.

The recommendation is based on the findings of the referral process initiated by the EMA. The document outlining the recommendation details the rationale behind the proposed revocation, focusing on the assessment of the drug's safety and efficacy profile.

Key Details of the Recommendation

The EMA's recommendation is a significant regulatory step that impacts the availability of Tavneos in the European market. The Article 20 procedure allows the agency to review the marketing authorization of a medicine when new information emerges that may affect its benefit-risk balance.

Aspect	Detail
Company	Amgen
Product	Tavneos
Procedure	Article 20
Recommendation	Revocation of marketing authorization

The final decision on the revocation of the marketing authorization will be made by the European Commission, which generally follows the EMA's recommendations. Healthcare professionals and patients will be notified of the outcome and any necessary actions to be taken.

How will this regulatory setback impact Amgen's financial guidance for the upcoming fiscal year?

Will the EMA's decision influence the review status or labeling of Tavneos in other major markets, such as the US?

What alternative treatment options are available for European patients currently relying on Tavneos?